Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

1.250 -0.040 (-3.10%)
Streaming Delayed Price Updated: 3:03 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tharimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Via ACCESS Newswire
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Via ACCESS Newswire
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
Tharimmune just reported results for the second quarter of 2024. 
Via InvestorPlace
Tharimmune to Present at the Microcap Conference 2025
Via ACCESS Newswire
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Via ACCESSWIRE
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
What's Going On With Tharimmune Shares Monday?
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver... 
Via Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Via ACCESSWIRE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Via ACCESSWIRE
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
S&P 500 Edges Lower; US Crude Oil Inventories Fall
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
What's Going On With Tharimmune Shares Wednesday?
Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Via ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Via ACCESSWIRE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Via ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Via ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS